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Treatment resistant depression (TRD) is a major public health issue, with comorbid
OCD contributing to the general medical costs and severity associated with TRD.
Recent research has investigated the efficacy of transcranial magnetic stimulation
(TMS and its variant rTMS) in ameliorating the symptoms of depression and OCD.
Most studies have used TMS to facilitate electromagnetic stimulation of the
dorsolateral prefrontal cortex, a region implicated in depression, or the supplemental
motor area, a region implicated in OCD. However, it is difficult to achieve full
remission with TMS alone. A parallel line of research has examined the effects of
ketamine, an N-methyl-D-aspartate (NMDA) antagonist, on both depression and OCD.
A primary benefit of ketamine is that it provides short-term but rapid relief from
certain grave TRD symptoms within approximately two hours. As of yet, little is known
about the possible synergistic effects of combined TMS/ketamine for comorbid TRD
and OCD. Thus, I report on the case of a 32-year-old male who presented with
chronic OCD with somatic fixation, depression, and generalized anxiety disorder, who
was treated with a novel combined TMS/ketamine treatment for 12 weeks. Measures of
depression and OCD symptoms were administered pre and post treatment. The patient
showed significant reductions in depression, but not OCD symptoms, which is consistent
with previous research.
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Treatment resistant depression (TRD) is a major public health issue, with at least 20%
of patients failing to respond to more than one traditional antidepressant (Crown et al.
2002; Sackeim 2001). In addition, TRD is associated with general medical costs esti-
mated to be 19 times greater than those stemming from treatment responsive depres-
sion (Sackeim 2001). A factor that may contribute to treatment resistance is the high
degree of comorbidity with a variety of mental disorders. For example, approximately
33% of depressed individuals also meet diagnostic criteria for OCD (Masellis et al.
2003). To address these challenges, recent research has investigated the efficacy of
transcranial magnetic stimulation (TMS and its variant rTMS) in ameliorating the
symptoms of depression and OCD (Gross et al. 2007; Mantovani et al. 2010). Most
studies have used TMS to facilitate electromagnetic stimulation of the dorsolateral pre-
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OCD. However, it is difficult to achieve full remission with TMS alone. A parallel line
of research has examined the effects of ketamine, an N-methyl-D-aspartate (NMDA)
antagonist, on both depression (Berman et al. 2000; Diazgranados et al. 2010; Murrough
et al. 2012; Zarate et al. 2006; Zarate et al. 2012; Ibrahim et al. 2012) and OCD (Bloch
et al. 2012). A primary benefit of ketamine is that it provides short-term but rapid relief
from certain grave TRD symptoms within approximately two hours. As of yet, little is
known about the possible synergistic effects of combined TMS/ketamine for comorbid
TRD and OCD.
One study suggested that a factor implicated in TRD is dysregulation of a thalamo-
cortical circuit encompassing the anterior cingulate cortex (ACC) and other areas
(LLínas et al. 1999). Research has also shown abnormalities in ACC neuronal function-
ing in OCD (Ursu et al. 2003). In addition, research has shown that the ACC can be af-
fected by TMS directed to the medial frontal cortex which overlays the ACC (Hayward
et al. 2007). Accordingly, I hypothesized that transcranial magnetic stimulation of the
medial frontal cortex would affect the ACC and thereby facilitate a less abnormal level
of functioning in the relevant thalamocortical circuit, and thus improve the response to
ketamine. I report on a chronically depressed patient with comorbid OCD first diag-
nosed in childhood who did not respond to numerous antidepressant medications, and
who was then treated with a novel combined ketamine/TMS technique. The patient
showed substantial improvement in depression symptomatology, though not in OCD
symptomatology, after 4 months of weekly treatments. An IRB exemption was obtained
from an independent accredited agency.
Case presentation
Patient X is a 32-year-old male who presented with chronic obsessive-compulsive dis-
order with somatic fixation, depression, and generalized anxiety disorder. Patient X was
treated with pharmacological interventions and psychotherapy for 50 months before
beginning ketamine/TMS treatment. During this initial treatment phase, Patient X’s
symptoms did not respond to treatment with the mood stabilizers (olanzapine and val-
proic acid), antidepressants (desvenlafaxine, sertraline, and fluvoxamine), anti-anxiety
medication (chlorazepate), psychostimulants (lis-dexamphetamine, and methylphenid-
ate), gabapentin, or conventional psychotherapy. Before beginning ketamine/TMS treat-
ment, Patient X had been coincidentally referred to a licensed psychologist for a
comprehensive pretreatment assessment of symptomatology. The assessment included
the Beck Depression Inventory-2 (BDI-II), the Beck Anxiety Inventory (BAI), the Beck
Hopelessness Scale (BHS), and the Personality Assessment Inventory (PAI), which in-
cludes subscales measuring a variety of psychopathology domains. PAI subscale scores
greater than 70 indicate clinically significant difficulties. At the pretreatment assessment,
Patient X exhibited severe levels of depression (BDI-II = 48) in terms of cognitions (PAI
DEP-C = 81), affect (PAI DEP-A = 77), and appraisals of hopelessness (BHS = 18). In
addition, Patient-X reported severe anxiety (BAI = 52). Related to these symptoms, Patient
X reported a high degree of suicidal ideation (PAI SUI = 89). Patient X also demonstrated
clinically significant levels of obsessive-compulsive symptoms (PAI ARD-O = 78). The
OCD symptoms included engaging in behavioral rituals to decrease anxiety, fear of losing
control of impulses and handling contaminated objects, a heightened need for order, high
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strong need to control his feelings and thoughts, and overarching perfectionism.
Prior to beginning combined treatment, Patient-X was given 2 days of rTMS pretreat-
ment (4 treatments per day of 30 minutes each with 45 minutes of rest between treat-
ments). Combined ketamine/TMS treatment began the following day and continued
twice per week for 10 weeks. Combined treatment consisted of 50 minutes of 1Hz con-
tinuous TMS with an intravenous ketamine infusion administered concurrent to and
bracketed within the middle 40 minutes of TMS, resulting in 5 minutes of TMS pre
and post infusion. The dosage of infused ketamine increased gradually from 40 mg at
the first treatment to a peak of 425 mg at the 12th treatment, and tapered down to
225 mg at the last treatment. The dose increases occurred in order to assist the patient
in reaching a mildly dissociated and cataleptic state. I hypothesized that greater dosages
were needed until central nervous system function reached a point of maximal
health. I defined this point as when both the patient and a close family member
rated the patient’s functioning as normal. Once normal functioning was achieved, I
began to taper the dosage. During combined treatment, the TMS head coil (manufac-
tured by Neotonus) was positioned at the midline (Fz on 10/20 positioning system) of
the anterior scalp to achieve maximal stimulation of the medial prefrontal area that
overlays the anterior cingulate, a region implicated in depression (Gross et al. 2007).
TMS treatments were administered at 115% of motor threshold (threshold of comfort
for this patient) at 1Hz continuous pulsation given that these settings were within
safety guidelines and consistent with my usual method. Using this method, I hypothe-
sized that the dissociative effects of ketamine along with TMS activation of the anterior
cingulate would help reestablish normal oscillatory rhythms in this region, leading to a
decrease in depression and OCD symptoms.
After 8 twice-weekly treatments, Patient X began to report improvements in mood
that increased throughout treatment. At post-treatment, Patient X was again evaluated,
by the same licensed psychologist for comprehensive assessment. At this assessment,
Patient X reported greatly decreased levels of depression (BDI-II = 13) in terms of cog-
nitions (PAI DEP-C = 61), affect (PAI DEP-A = 66), and appraisals of hopelessness
(BHS = 4). In addition, Patient X reported reduced anxiety (BAI = 24) and no ongoing
evidence of suicidal ideation (PAI SUI = 51). However, Patient X’s obsessive-compulsive
symptoms remained elevated (PAI ARD-O = 84).
Conclusions
This case report adds to the literature on improving the efficacy of brain electromag-
netic stimulation by administering pharmacological agents that modulate glutamatergic
transmission. Whereas previous research suggests that TMS is somewhat effective in
treating depression and OCD, and that sub-anesthetic doses of ketamine are temporar-
ily helpful with depression and OCD; the present case report suggests that a combined
ketamine/TMS treatment may be a more efficacious treatment for refractory depression
than either infused ketamine or TMS alone. However, this combined treatment did not
affect the OCD symptoms, which is partially consistent with a previous study showing
that ketamine had no lasting effect on OCD symptoms. Despite the promising findings
in this case report, one limitation is that I was not able to establish that placement
of the TMS coil stimulated the ACC as was hypothesized. Future research should
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should examine combined ketamine/TMS treatment in a randomized controlled trial.
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